Yaoguang She1, Jiao Liang1, Ying Qiu1, Na Liu1, Xiaohui Huang1, Xudong Zhao1, Peiyu Li2. 1. Departments of General Surgery, Chinese PLA General Hospital, Beijing 100853, China. 2. Departments of General Surgery, Chinese PLA General Hospital, Beijing 100853, China. Email: peiyuli301@163.com.
Abstract
OBJECTIVE: To explore the correlation between CD133 and proliferative marker Ki-67 in primary retroperitoneal leiomyosarcoma and evaluate their prognostic values. METHODS: A total of 50 primary retroperitoneal leiomyosarcoma samples were collected at our hospital from January 2000 to December 2012. There were 9 males and 41 females. All samples were analyzed for CD133 and Ki-67 protein expression by PV6000 immunohistochemistry. Their median age was 49 (27-75) years. All cases were successfully followed up. RESULTS: CD133 expression was detected in 74.00% (37/50) of primary retroperitoneal leiomyosarcoma samples. The CD133-positive rates of histological grades I & II primary leiomyosarcoma were 7/13 and 76.70% (23/30) respectively. All grade III samples (n = 7) were CD133 positive. And the expression of CD133 had a positive correlation with tumor size, mitotic counts and histological grade (χ(2) = 4.925, 4.525, 10.080; P = 0.026, 0.033, 0.013). The survival time of CD133-positive patients with M (Q1, Q3) was 32 (17, 56) months versus 44 (26, 65) months for those negative ones. The expression of Ki-67 was detected in 84.00% (42/50) of primary retroperitoneal leiomyosarcoma samples and its expression showed a positive correlation with mitotic counts. The expressions of CD133 and Ki-67 were positively correlated in primary retroperitoneal leiomyosarcomas (P = 0.009). Log-rank test showed that positive expressions of CD133 and Ki-67 and 5-year patient survival rate were correlated (P = 0.021, 0.049). Multivariate analysis showed that CD133 and mitotic counts were independent prognostic indicators for primary retroperitoneal leiomyosarcomas (HR = 2.040, 2.422; P = 0.000, 0.018). CONCLUSIONS: CD133 plays an important role in the progression of primary retroperitoneal leiomyosarcomas so that it may be used as a marker for patient prognosis. Combined detection of CD133 and Ki-67 has a prognostic value in patients with primary retroperitoneal leiomyosarcoma.
OBJECTIVE: To explore the correlation between CD133 and proliferative marker Ki-67 in primary retroperitoneal leiomyosarcoma and evaluate their prognostic values. METHODS: A total of 50 primary retroperitoneal leiomyosarcoma samples were collected at our hospital from January 2000 to December 2012. There were 9 males and 41 females. All samples were analyzed for CD133 and Ki-67 protein expression by PV6000 immunohistochemistry. Their median age was 49 (27-75) years. All cases were successfully followed up. RESULTS:CD133 expression was detected in 74.00% (37/50) of primary retroperitoneal leiomyosarcoma samples. The CD133-positive rates of histological grades I & II primary leiomyosarcoma were 7/13 and 76.70% (23/30) respectively. All grade III samples (n = 7) were CD133 positive. And the expression of CD133 had a positive correlation with tumor size, mitotic counts and histological grade (χ(2) = 4.925, 4.525, 10.080; P = 0.026, 0.033, 0.013). The survival time of CD133-positive patients with M (Q1, Q3) was 32 (17, 56) months versus 44 (26, 65) months for those negative ones. The expression of Ki-67 was detected in 84.00% (42/50) of primary retroperitoneal leiomyosarcoma samples and its expression showed a positive correlation with mitotic counts. The expressions of CD133 and Ki-67 were positively correlated in primary retroperitoneal leiomyosarcomas (P = 0.009). Log-rank test showed that positive expressions of CD133 and Ki-67 and 5-year patient survival rate were correlated (P = 0.021, 0.049). Multivariate analysis showed that CD133 and mitotic counts were independent prognostic indicators for primary retroperitoneal leiomyosarcomas (HR = 2.040, 2.422; P = 0.000, 0.018). CONCLUSIONS:CD133 plays an important role in the progression of primary retroperitoneal leiomyosarcomas so that it may be used as a marker for patient prognosis. Combined detection of CD133 and Ki-67 has a prognostic value in patients with primary retroperitoneal leiomyosarcoma.